Aytu Bioscience Stock Market Capitalization

AYTU Stock

USD 1.62 0.02 1.25%

Aytu BioScience fundamentals help investors to digest information that contributes to Aytu BioScience's financial success or failures. It also enables traders to predict the movement of Aytu Stock. The fundamental analysis module provides a way to measure Aytu BioScience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aytu BioScience stock.

		Last Reported	Projected for Next Year
	Market Cap	15.8 M	17.9 M

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aytu BioScience Company Market Capitalization Analysis

Aytu BioScience's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Market Cap

Shares Outstanding

X

Share Price

More About Market Capitalization | All Equity Analysis

Current Aytu BioScience Market Capitalization

9.84 M

Most of Aytu BioScience's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aytu BioScience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Aytu Market Capitalization Driver Correlations

Understanding the fundamental principles of building solid financial models for Aytu BioScience is extremely important. It helps to project a fair market value of Aytu Stock properly, considering its historical fundamentals such as Market Capitalization. Since Aytu BioScience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aytu BioScience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aytu BioScience's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Current Deferred Revenue	Capital Surpluse	Intangible Assets	Property Plant Equipment	Net Receivables	Good Will	Deferred Long Term Liab	Long Term Debt	Short Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		0.92	-0.56	-0.72	0.97	0.95	0.98	0.67	-0.43	-0.26	0.83	0.86	0.96	0.87	0.85	0.83	-0.68	0.33	-0.63	0.57	0.97	0.18	0.3	-0.25
Total Stockholder Equity	0.92		-0.74	-0.41	0.89	0.74	0.87	0.74	-0.35	0.06	0.6	0.64	0.84	0.68	0.59	0.55	-0.52	0.13	-0.48	0.65	0.97	0.35	0.53	0.03
Net Debt	-0.56	-0.74		0.13	-0.55	-0.34	-0.56	-0.27	0.3	-0.56	-0.04	-0.44	-0.44	-0.1	-0.13	-0.19	0.42	-0.19	0.38	-0.15	-0.63	-0.85	-0.85	-0.09
Retained Earnings	-0.72	-0.41	0.13		-0.72	-0.89	-0.8	-0.17	0.49	0.61	-0.84	-0.93	-0.81	-0.78	-0.92	-0.96	0.78	-0.7	0.74	-0.04	-0.57	0.03	0.07	0.58
Accounts Payable	0.97	0.89	-0.55	-0.72		0.92	0.96	0.61	-0.44	-0.27	0.84	0.83	0.97	0.83	0.84	0.78	-0.69	0.38	-0.63	0.49	0.92	0.19	0.31	-0.09
Total Liab	0.95	0.74	-0.34	-0.89	0.92		0.96	0.54	-0.45	-0.5	0.92	0.93	0.95	0.93	0.97	0.96	-0.74	0.46	-0.68	0.43	0.86	0.02	0.08	-0.43
Total Current Assets	0.98	0.87	-0.56	-0.8	0.96	0.96		0.56	-0.44	-0.26	0.82	0.91	0.95	0.84	0.89	0.88	-0.71	0.41	-0.66	0.45	0.94	0.24	0.31	-0.33
Short Term Debt	0.67	0.74	-0.27	-0.17	0.61	0.54	0.56		-0.3	-0.2	0.52	0.32	0.58	0.68	0.45	0.35	-0.21	-0.31	-0.16	0.94	0.72	-0.24	-0.01	0.0
Common Stock	-0.43	-0.35	0.3	0.49	-0.44	-0.45	-0.44	-0.3		0.16	-0.32	-0.59	-0.48	-0.34	-0.36	-0.4	0.63	-0.49	0.58	0.01	-0.32	-0.15	-0.09	0.18
Net Tangible Assets	-0.26	0.06	-0.56	0.61	-0.27	-0.5	-0.26	-0.2	0.16		-0.68	-0.36	-0.39	-0.64	-0.63	-0.59	0.37	-0.3	0.34	-0.19	-0.11	0.73	0.72	0.33
Current Deferred Revenue	0.83	0.6	-0.04	-0.84	0.84	0.92	0.82	0.52	-0.32	-0.68		0.76	0.9	0.96	0.95	0.88	-0.58	0.38	-0.54	0.46	0.72	-0.28	-0.13	-0.26
Capital Surpluse	0.86	0.64	-0.44	-0.93	0.83	0.93	0.91	0.32	-0.59	-0.36	0.76		0.88	0.77	0.87	0.93	-0.86	0.67	-0.81	0.15	0.75	0.24	0.21	-0.53
Intangible Assets	0.96	0.84	-0.44	-0.81	0.97	0.95	0.95	0.58	-0.48	-0.39	0.9	0.88		0.9	0.88	0.86	-0.73	0.46	-0.67	0.44	0.89	0.11	0.24	-0.18
Property Plant Equipment	0.87	0.68	-0.1	-0.78	0.83	0.93	0.84	0.68	-0.34	-0.64	0.96	0.77	0.9		0.92	0.87	-0.59	0.27	-0.56	0.62	0.81	-0.29	-0.11	-0.35
Net Receivables	0.85	0.59	-0.13	-0.92	0.84	0.97	0.89	0.45	-0.36	-0.63	0.95	0.87	0.88	0.92		0.96	-0.65	0.44	-0.61	0.38	0.74	-0.16	-0.12	-0.48
Good Will	0.83	0.55	-0.19	-0.96	0.78	0.96	0.88	0.35	-0.4	-0.59	0.88	0.93	0.86	0.87	0.96		-0.72	0.53	-0.68	0.27	0.7	-0.04	-0.04	-0.59
Deferred Long Term Liab	-0.68	-0.52	0.42	0.78	-0.69	-0.74	-0.71	-0.21	0.63	0.37	-0.58	-0.86	-0.73	-0.59	-0.65	-0.72		-0.82	0.97	0.0	-0.59	-0.27	-0.2	0.32
Long Term Debt	0.33	0.13	-0.19	-0.7	0.38	0.46	0.41	-0.31	-0.49	-0.3	0.38	0.67	0.46	0.27	0.44	0.53	-0.82		-0.85	-0.5	0.2	0.32	0.17	-0.22
Short Term Investments	-0.63	-0.48	0.38	0.74	-0.63	-0.68	-0.66	-0.16	0.58	0.34	-0.54	-0.81	-0.67	-0.56	-0.61	-0.68	0.97	-0.85		0.03	-0.56	-0.27	-0.18	0.3
Short Long Term Debt	0.57	0.65	-0.15	-0.04	0.49	0.43	0.45	0.94	0.01	-0.19	0.46	0.15	0.44	0.62	0.38	0.27	0.0	-0.5	0.03		0.65	-0.33	-0.09	0.01
Net Invested Capital	0.97	0.97	-0.63	-0.57	0.92	0.86	0.94	0.72	-0.32	-0.11	0.72	0.75	0.89	0.81	0.74	0.7	-0.59	0.2	-0.56	0.65		0.24	0.4	-0.16
Net Working Capital	0.18	0.35	-0.85	0.03	0.19	0.02	0.24	-0.24	-0.15	0.73	-0.28	0.24	0.11	-0.29	-0.16	-0.04	-0.27	0.32	-0.27	-0.33	0.24		0.89	0.12
Capital Stock	0.3	0.53	-0.85	0.07	0.31	0.08	0.31	-0.01	-0.09	0.72	-0.13	0.21	0.24	-0.11	-0.12	-0.04	-0.2	0.17	-0.18	-0.09	0.4	0.89		0.25
Long Term Debt Total	-0.25	0.03	-0.09	0.58	-0.09	-0.43	-0.33	0.0	0.18	0.33	-0.26	-0.53	-0.18	-0.35	-0.48	-0.59	0.32	-0.22	0.3	0.01	-0.16	0.12	0.25

Click cells to compare fundamentals

Aytu Market Capitalization Historical Pattern

Today, most investors in Aytu BioScience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aytu BioScience's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's market capitalization growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Aytu BioScience market capitalization as a starting point in their analysis.

Aytu BioScience Market Capitalization

Timeline

In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Competition

Predict Aytu BioScience

Market Cap Over Time

Aytu Long Term Debt To Capitalization

Long Term Debt To Capitalization

0.16

At this time, Aytu BioScience's Long Term Debt To Capitalization is comparatively stable compared to the past year.

Based on the recorded statements, the market capitalization of Aytu BioScience is about 9.84 M. This is 99.92% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The market capitalization for all United States stocks is 99.95% higher than that of the company.

Aytu Market Capitalization Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aytu BioScience's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aytu BioScience could also be used in its relative valuation, which is a method of valuing Aytu BioScience by comparing valuation metrics of similar companies.

Aytu BioScience is currently under evaluation in market capitalization category among its peers.

Aytu Fundamentals

	Return On Equity	-0.47
	Return On Asset	-0.0106
	Profit Margin	(0.20) %
	Operating Margin	(0.04) %
	Current Valuation	6.29 M
	Shares Outstanding	6.15 M
	Shares Owned By Insiders	2.43 %
	Shares Owned By Institutions	34.04 %
	Number Of Shares Shorted	192.76 K
	Price To Earning	(0.77) X
	Price To Book	0.33 X
	Price To Sales	0.12 X
	Revenue	81 M
	Gross Profit	66.63 M
	EBITDA	(1.01 M)
	Net Income	(15.84 M)
	Cash And Equivalents	23.81 M
	Cash Per Share	0.38 X
	Total Debt	15.13 M
	Debt To Equity	0.47 %
	Current Ratio	1.02 X
	Book Value Per Share	4.64 X
	Cash Flow From Operations	(1.39 M)
	Short Ratio	10.45 X
	Earnings Per Share	(1.70) X
	Target Price	8.0
	Number Of Employees	102
	Beta	-1.4
	Market Capitalization	9.84 M
	Total Asset	118.09 M
	Retained Earnings	(319.97 M)
	Working Capital	(337 K)
	Current Asset	6.36 M
	Current Liabilities	8.73 M
	Net Asset	118.09 M

About Aytu BioScience Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aytu BioScience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aytu BioScience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aytu BioScience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aytu Stock Analysis

When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC